Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



DaVita Clinical Research to Present Research Results on Hospital Readmissions, Anemia Management, Nutrition

DaVita Clinical Research to Present Research Results on Hospital Readmissions, Anemia Management, Nutrition

ORLANDO, Fla.--(BUSINESS WIRE)-- DaVita Clinical Research® (DCR®), a specialty contract research organization with services spanning the full spectrum of drug and device development, today announced that company representatives will present four abstracts at National Kidney Foundation's (NKF) 2013 Spring Clinical Meeting, which takes place April 2-6, 2013, in Orlando, Fla.

The NKF Spring Clinical Meeting is a platform for the nation's leading renal health care providers to learn about new developments in the field of nephrology and kidney care practices.

Researchers from DaVita®, the dialysis division of DaVita Healthcare Partners Inc., and DCR will present results from a number of innovative clinical improvement programs originating from DaVita and its research partners. DCR provides a collaborative bridge between DaVita’s health care community and the academic, pharmaceutical and biotech research community. DCR and DaVita share a dedication to improving the health and quality of life for kidney care patients.

DCR’s recent research includes analyses of hospital readmissions and length of stay, new findings on anemia management and work on nutritional issues.

“Clinical research is a critical part of DaVita’s work to alleviate suffering and reduce health care costs related to chronic kidney disease and end stage renal disease,” said Mahesh Krishnan, M.D., M.P.H., M.B.A., F.A.S.N., vice president of clinical research. “These abstracts are the result of significant investments in clinical research, and we believe the findings demonstrate the value of that investment.”

At this year's NKF Spring Clinical Meeting, DaVita will focus on several key research initiatives in end-stage renal disease, including:

  • “Analysis of Length of Stay (LOS) and Readmissions Among End-Stage Renal Disease (ESRD) and Non-ESRD Patients Using a 5% Sample of Inpatient Claims Data From the Centers for Medicare and Medicaid Services (CMS) (2007-2008)” [Poster 128]
  • “Evaluating Hemoglobin (HB) Trends and the Potential Impact on Transfusions (TFNS) Under the New ESA Guidelines in Patients with ESRD at a Large Dialysis Organization” [Poster 48]
  • “Timing of Albumin Testing Affects Corrected Calcium Levels” [Poster 115]
  • “Multiple Anemia Protocols Permit Anemia Control and Physician Choice” [Poster 48]

DaVita, DaVita Clinical Research, DCR and DaVita HealthCare Partners are trademarks or registered trademarks of DaVita Healthcare Partners Inc. All other trademarks are the property of their respective owners.

About DaVita

DaVita is the dialysis division of DaVita HealthCare Partners Inc., a Fortune 500® company that, through its operating divisions, provides a variety of health care services to patient populations throughout the United States and abroad. A leading provider of kidney care in the United States, DaVita delivers dialysis services to patients with chronic kidney failure and end stage renal disease. DaVita strives to improve patients’ quality of life by innovating clinical care, and by offering integrated treatment plans, personalized care teams and convenient health-management services. As of Dec.31, 2012, DaVita operated or provided administrative services at 1,954 outpatient dialysis centers located in the United States serving approximately 153,000 patients. The company also operated 36 outpatient dialysis centers located in eight countries outside the United States. DaVita supports numerous programs dedicated to creating positive, sustainable change in communities around the world. The company’s leadership development initiatives and social responsibility efforts have been recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu. For more information, please visit

About DaVita Clinical Research

DaVita Clinical Research (DCR), a wholly owned subsidiary of DaVita HealthCare Partners Inc., uses its extensive, applied database and real-world healthcare experience to assist pharmaceutical and medical device companies in the design, recruitment, and completion of clinical trials including retrospective and prospective pragmatic trials. DCR’s scientific and clinical expertise spans the lifecycle of product development with more than 150 client companies. DCR’s BiorepositoryEarly Clinical Research unit (Phase I-IIa) and Clinical Development (Phase IIb through post-marketing) network of physicians and investigative sites, data research, Health Economics & Outcomes ResearchCentral Laboratory, and Medical Communications are focused on providing world-class research in both complex/specialty populations and therapeutic areas, and especially in CKD and ESRD populations. To learn more about DCR, visit

DaVita Clinical Research
Bianca Violante
Office: 303-876-661
Mobile: 443-417-6044

KEYWORDS:   United States  North America  Florida


Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2345777, ~/Articles/ArticleHandler.aspx, 9/2/2015 6:58:20 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...